Homeopathy assuages side effects of Rx

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 5
Volume 18
Issue 5

Homeopathy can help cancer patients with skin irritation and mouth sores, according to a review involving 664 participants published in the Cochrane Database of Systematic Reviews (online issue 2, 2009).

Homeopathy can help cancer patients with skin irritation and mouth sores, according to a review involving 664 participants published in the Cochrane Database of Systematic Reviews (online issue 2, 2009).

Sosie Kassab, MD, director of the Royal London Homeopathic Hospital’s Complementary Cancer Service, and colleagues reviewed eight studies on homeopathic remedies.

In one study with 256 participants, researchers found skin irritation from radiotherapy was less in patients who used calendula ointment as opposed to the topical agent trolamine. In another study with 32 participants, the hemeopathic, Traumeel S, relieved mouth sores caused by chemotherapy better than placebo.

There is no convincing evidence to support the use of homeopathic medicines for adverse effects of cancer treatments other than skin irritation and mouth sores, Dr. Kassab said. “But very little research has been undertaken and more is required,” she said.

Most physicians are unaware that major, federally funded clinical trials on alternative medicine are currently underway (Arch Intern Med 169:670-679, 2009).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content